OCUGEN INC. - COMMON

Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU400—Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication

10 Apr 2024 06:02:26 By Nasdaq GlobeNewswire

Ocugen, Inc. Announces U.S. FDA Clearance of IND Amendment to Initiate OCU400 Phase 3 Clinical Trial — First Gene Therapy to Enter Phase 3 with a Broad Retinitis Pigmentosa Indication

08 Apr 2024 05:30:43 By Nasdaq GlobeNewswire

Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410—a Modifier Gene Therapy—in Phase 1/2 ArMaDa Study for Geographic Atrophy

05 Apr 2024 06:02:21 By Nasdaq GlobeNewswire

Ocugen Provides Business Update with Certain Financials for the Year Ending 2023

02 Apr 2024 07:00:39 By Nasdaq GlobeNewswire

Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410ST—a Modifier Gene Therapy—in GARDian Study for Stargardt Disease

01 Apr 2024 17:08:46 By Nasdaq GlobeNewswire

Ocugen to Host Conference Call on Tuesday, April 2 at 8:30 A.M. ET to Provide Business Update with Certain Financials for the Year Ending 2023

01 Apr 2024 16:43:45 By Nasdaq GlobeNewswire

Ocugen, Inc. Appoints Huma Qamar, MD, MPH as Chief Medical Officer

18 Mar 2024 05:30:50 By Nasdaq GlobeNewswire

Ocugen, Inc. Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410

13 Mar 2024 07:00:54 By Nasdaq GlobeNewswire

Ocugen to Present at Investing in Cures Summit

06 Mar 2024 06:30:09 By Nasdaq GlobeNewswire

Ocugen Clinical Showcase Webcast Now Available

28 Feb 2024 07:00:26 By Nasdaq GlobeNewswire

Ocugen Chairman and CEO to present at Abu Dhabi Family Office Summit

26 Feb 2024 07:30:13 By Nasdaq GlobeNewswire

Ocugen, Inc. Announces Dosing Completion of Subjects with Stargardt in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST

22 Feb 2024 15:05:00 By Nasdaq GlobeNewswire

Ocugen to Present at 2024 BIO CEO & Investor Conference

21 Feb 2024 15:05:00 By Nasdaq GlobeNewswire

Ocugen to Host Clinical Showcase in New York City on Wednesday, February 21, 2024

14 Feb 2024 06:30:49 By Nasdaq GlobeNewswire

Ocugen to Present at Pharma Market Research Conference

31 Jan 2024 07:00:12 By Nasdaq GlobeNewswire

Ocugen, Inc. Announces Bob Smith Joins Business Advisory Board

16 Jan 2024 06:30:58 By Nasdaq GlobeNewswire

Ocugen Gains FDA Alignment on Key Aspects of OCU400—Modifier Gene Therapy—Pivotal Phase 3 Study Design

21 Dec 2023 05:30:09 By Nasdaq GlobeNewswire

Ocugen Announces OCU400 Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Retinitis Pigmentosa Associated with RHO Mutations

19 Dec 2023 06:30:00 By Nasdaq GlobeNewswire

Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410—Modifier Gene Therapy—for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

13 Dec 2023 06:30:14 By Nasdaq GlobeNewswire

Ocugen CEO to Present at NobleCon19 – Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity Conference

29 Nov 2023 06:30:12 By Nasdaq GlobeNewswire